{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:56:41Z","timestamp":1793321801125,"version":"4.5.0"},"reference-count":198,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Glucocorticoids are effective immunomodulatory drugs used for many inflammatory disorders as well as in transplant recipients. However, both iatrogenic and endogenous glucocorticoid excess are also associated with several side effects including an increased risk of osteoporosis and fractures. Glucocorticoid-induced osteoporosis (GIOP) is a common secondary cause of osteoporosis in adults. Despite availability of clear evidence and international guidelines for the prevention of GIOP, a large treatment gap remains. In this narrative review, the Belgian Bone Club (BBC) updates its 2006 consensus recommendations for the prevention and treatment of GIOP in adults. The pathophysiology of GIOP is multifactorial. The BBC strongly advises non-pharmacological measures including physical exercise, smoking cessation and avoidance of alcohol abuse in all adults at risk for osteoporosis. Glucocorticoids are associated with impaired intestinal calcium absorption; the BBC therefore strongly recommend sufficient calcium intake and avoidance of vitamin D deficiency. We recommend assessment of fracture risk, taking age, sex, menopausal status, prior fractures, glucocorticoid dose, other clinical risk factors and bone mineral density into account. Placebo-controlled randomized controlled trials have demonstrated the efficacy of alendronate, risedronate, zoledronate, denosumab and teriparatide in GIOP. We suggest monitoring by dual-energy X-ray absorptiometry (DXA) and vertebral fracture identification one year after glucocorticoid initiation. The trabecular bone score might be considered during DXA monitoring. Extended femur scans might be considered at the time of DXA imaging in glucocorticoid users on long-term (\u2265 3 years) antiresorptive therapy. Bone turnover markers may be considered for monitoring treatment with anti-resorptive or osteoanabolic drugs in GIOP. Although the pathophysiology of solid organ and hematopoietic stem cell transplantation-induced osteoporosis extends beyond GIOP alone, the BBC recommends similar evaluation, prevention, treatment and follow-up principles in these patients. Efforts to close the treatment gap in GIOP and implement available effective fracture prevention strategies into clinical practice in primary, secondary and tertiary care are urgently needed.<\/jats:p>","DOI":"10.3389\/fendo.2022.908727","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T13:17:05Z","timestamp":1654780625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":99,"title":["Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club"],"prefix":"10.3389","volume":"13","author":[{"given":"Micha\u00ebl R.","family":"Laurent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Goemaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Verroken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Cavalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lapauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Gielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000647","article-title":"Monitoring of Patients on Long-Term Glucocorticoid Therapy: A Population-Based Cohort Study","volume":"94","author":"Fardet","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.05.007","article-title":"Regional Differences in Treatment for Osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)","volume":"49","author":"Diez-Perez","year":"2011","journal-title":"Bone"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040134","article-title":"A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4033","article-title":"The Effect of Biochemical Remission on Bone Metabolism in Cushing's Syndrome: A 2-Year Follow-Up Study","volume":"35","author":"Braun","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-10-199311150-00001","article-title":"Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients With Rheumatoid Arthritis. A Randomized, Controlled Study","volume":"119","author":"Laan","year":"1993","journal-title":"Ann Intern Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3455-9","article-title":"Fracture Risk in Oral Glucocorticoid Users: A Bayesian Meta-Regression Leveraging Control Arms of Osteoporosis Clinical Trials","volume":"27","author":"Amiche","year":"2016","journal-title":"Osteoporos Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05360-w","article-title":"Effects of Glucocorticoids on Osteoporosis in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis","volume":"31","author":"Wang","year":"2020","journal-title":"Osteoporos Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of Oral Corticosteroids and Risk of Fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J Bone Miner Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3523","article-title":"Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions","volume":"33","author":"Balasubramanian","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-Term Systemic Corticosteroid Exposure: A Systematic Literature Review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s001980200108","article-title":"The Epidemiology of Corticosteroid-Induced Osteoporosis: A Meta-Analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Clinical Practice. Glucocorticoid-Induced Bone Disease","volume":"365","author":"Weinstein","year":"2011","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral Corticosteroids and Fracture Risk: Relationship to Daily and Cumulative Doses","volume":"39","author":"van Staa","year":"2000","journal-title":"Rheumatol (Oxford)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11657-018-0424-x","article-title":"Impact of Cumulative Exposure to High-Dose Oral Glucocorticoids on Fracture Risk in Denmark: A Population-Based Case-Control Study","volume":"13","author":"Amiche","year":"2018","journal-title":"Arch Osteoporos"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2520-5","article-title":"Bone Complications in Patients With Cushing's Syndrome: Looking for Clinical, Biochemical, and Genetic Determinants","volume":"25","author":"Trementino","year":"2014","journal-title":"Osteoporos Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11657-015-0244-1","article-title":"The Risk Factors for Fractures and Trabecular Bone-Score Value in Patients With Endogenous Cushing's Syndrome","volume":"10","author":"Belaya","year":"2015","journal-title":"Arch Osteoporos"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3947","article-title":"Involvement of the Gut Microbiota and Barrier Function in Glucocorticoid-Induced Osteoporosis","volume":"35","author":"Schepper","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-014-0197-0","article-title":"The Role of Wnt Signaling and Sclerostin in the Pathogenesis of Glucocorticoid-Induced Osteoporosis","volume":"12","author":"Guanabens","year":"2014","journal-title":"Curr Osteoporos Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_340","article-title":"Drugs Causing Bone Loss","volume":"262","author":"Vestergaard","year":"2020","journal-title":"Handb Exp Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-022-01323-9","article-title":"Bone Biopsy Findings in Patients Receiving Long-Term Bisphosphonate Therapy for Glucocorticoid-Induced Osteoporosis","author":"Takahata","year":"2022","journal-title":"J Bone Miner Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13474","article-title":"Loss of Glucocorticoid Rhythm Induces an Osteoporotic Phenotype in Female Mice","volume":"20","author":"Schilperoort","year":"2021","journal-title":"Aging Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2174\/1573397115666190723160312","article-title":"Is Rheumatoid Arthritis a Risk Factor for Fractures: A Systematic Review of Observational Studies","volume":"16","author":"Gupta","year":"2020","journal-title":"Curr Rheumatol Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.3.581","article-title":"Use of Inhaled Corticosteroids and Risk of Fractures","volume":"16","author":"van Staa","year":"2001","journal-title":"J Bone Miner Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.06.008","article-title":"The Effect of Glucocorticoids on Bone Mineral Density in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials","volume":"114","author":"Blavnsfeldt","year":"2018","journal-title":"Bone"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22519","article-title":"Meta-Analysis of Tumor Necrosis Factor Inhibitors and Glucocorticoids on Bone Density in Rheumatoid Arthritis and Ankylosing Spondylitis Trials","volume":"67","author":"Siu","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-019-0667-1","article-title":"A Meta-Analysis of Secondary Osteoporosis in Systemic Lupus Erythematosus: Prevalence and Risk Factors","volume":"15","author":"Gu","year":"2019","journal-title":"Arch Osteoporos"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e000590","DOI":"10.1136\/lupus-2021-000590","article-title":"Impact of Glucocorticoids on the Incidence of Lupus-Related Major Organ Damage: A Systematic Literature Review and Meta-Regression Analysis of Longitudinal Observational Studies","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.05.005","article-title":"Prevalence and Risk Factors of Low Bone Mineral Density in Psoriatic Arthritis: A Systematic Review","volume":"46","author":"Chandran","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40169-020-00270-0","article-title":"Bone Mineral Density is Negatively Correlated With Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"9","author":"Zhou","year":"2020","journal-title":"Clin Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001031","article-title":"Risk of Fractures in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis","volume":"53","author":"Komaki","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.14309\/ajg.0000000000000062","article-title":"Fracture Risk in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study From 1964 to 2014","volume":"114","author":"Ludvigsson","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080890","article-title":"Bisphosphonates for the Prevention and Treatment of Osteoporosis in Patients With Rheumatic Diseases: A Systematic Review and Meta-Analysis","volume":"8","author":"Feng","year":"2013","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1812835","article-title":"Efficacy and Safety of Sodium RISedronate for Glucocorticoid-Induced OsTeoporosis With Rheumatoid Arthritis (RISOTTO Study): A Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial","volume":"31","author":"Fujieda","year":"2021","journal-title":"Mod Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005861","article-title":"Efficacy and Safety of Bisphosphonates in Management of Low Bone Density in Inflammatory Bowel Disease: A Meta-Analysis","volume":"96","author":"Yao","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci029","article-title":"A Simple Score for Estimating the Long-Term Risk of Fracture in Patients Using Oral Glucocorticoids","volume":"98","author":"van Staa","year":"2005","journal-title":"QJM"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50758","article-title":"Cumulative Dispensing of High Oral Corticosteroid Doses for Treating Asthma in Australia","volume":"213","author":"Hew","year":"2020","journal-title":"Med J Aust"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in Severe Asthma Requiring Systemic Corticosteroid Therapy: Cross-Sectional Data From the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1479973119838280","DOI":"10.1177\/1479973119838280","article-title":"Mortality and Vertebral Fracture Risk Associated With Long-Term Oral Steroid Use in Patients With Chronic Obstructive Pulmonary Disease: A Systemic Review and Meta-Analysis","volume":"16","author":"Chang","year":"2019","journal-title":"Chron Respir Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of Long-Term Oral Corticosteroid Therapy and its Side-Effects in Severe Asthma in Adults: A Focused Review of the Impact Data in the Literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.semarthrit.2014.02.002","article-title":"A Systematic Review and Meta-Analysis of Glucocorticoid-Induced Osteoporosis in Children","volume":"44","author":"Hansen","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"B42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.maturitas.2020.05.004","article-title":"How to Manage Osteoporosis Before the Age of 50","volume":"138","author":"Rozenberg","year":"2020","journal-title":"Maturitas"},{"key":"B43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00198-005-2032-z","article-title":"Evidence-Based Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: A Consensus Document of the Belgian Bone Club","volume":"17","author":"Devogelaer","year":"2006","journal-title":"Osteoporos Int"},{"key":"B44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.maturitas.2020.05.006","article-title":"The Belgian Bone Club 2020 Guidelines for the Management of Osteoporosis in Postmenopausal Women","volume":"139","author":"Sanchez-Rodriguez","year":"2020","journal-title":"Maturitas"},{"key":"B45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jclinepi.2015.11.017","article-title":"A Guide for Health Professionals to Interpret and Use Recommendations in Guidelines Developed With the GRADE Approach","volume":"72","author":"Neumann","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-1096","article-title":"Reduction in Daily Hydrocortisone Dose Improves Bone Health in Primary Adrenal Insufficiency","volume":"174","author":"Schulz","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.9.941","article-title":"Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-Analysis","volume":"159","author":"Lipworth","year":"1999","journal-title":"Arch Intern Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/art.22294","article-title":"Fracture Risk With Intermittent High-Dose Oral Glucocorticoid Therapy","volume":"56","author":"De Vries","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B49","doi-asserted-by":"publisher","first-page":"CD006897","DOI":"10.1002\/14651858.CD006897.pub4","article-title":"Different Durations of Corticosteroid Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease","volume":"3","author":"Walters","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40520-021-01823-0","article-title":"Management of Glucocorticoid-Induced Osteoporosis","volume":"33","author":"Messina","year":"2021","journal-title":"Aging Clin Exp Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2442-2","article-title":"Risk of Fracture in Patients With Muscular Dystrophies","volume":"25","author":"Pouwels","year":"2014","journal-title":"Osteoporos Int"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15735","article-title":"The Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Immune Thrombocytopenia Receiving Steroids: A British Society for Haematology Good Practice Paper","volume":"185","author":"Hill","year":"2019","journal-title":"Br J Haematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1177\/1076029609350889","article-title":"Effects of Bisphosphonate Administration on the Bone Mass in Immune Thrombocytopenic Purpura Patients Under Treatment With Steroids","volume":"16","author":"Nomura","year":"2010","journal-title":"Clin Appl Thromb Hemost"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18104","article-title":"Bone Health and Glucocorticoid-Containing Lymphoma Therapy - a Review of Risk Factors and Preventative Measures","author":"Eyre","year":"2022","journal-title":"Br J Haematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01761.x","article-title":"Long-Term Follow-Up of Bone Mineral Density in Addison's Disease","volume":"58","author":"Jodar","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12020-021-02723-z","article-title":"Rate of Fracture in Patients With Glucocorticoid Replacement Therapy: A Systematic Review and Meta-Analysis","volume":"74","author":"Li","year":"2021","journal-title":"Endocrine"},{"key":"B57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4158\/EP161428.OR","article-title":"Glucocorticoid Replacement Regimens in Chronic Adrenal Insufficiency: A Systematic Review and Meta-Analysis","volume":"23","author":"Al Nofal","year":"2017","journal-title":"Endocr Pract"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0160","article-title":"Prednisolone is Associated With a Worse Bone Mineral Density in Primary Adrenal Insufficiency","volume":"7","author":"Frey","year":"2018","journal-title":"Endocr Connect"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00493","article-title":"Bone Mineral Density in Adults With Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis","volume":"11","author":"Rangaswamaiah","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.18.02867-5","article-title":"Bone Health Among Patients With Primary Aldosteronism: A Systematic Review and Meta-Analysis","volume":"44","author":"Loh","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93136","article-title":"Steroid Metabolome Analysis Reveals Prevalent Glucocorticoid Excess in Primary Aldosteronism","volume":"2","author":"Arlt","year":"2017","journal-title":"JCI Insight"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1398-z","article-title":"Inhaled Corticosteroids Effects on Bone in Asthmatic and COPD Patients: A Quantitative Systematic Review","volume":"14","author":"Richy","year":"2003","journal-title":"Osteoporos Int"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831050-00005","article-title":"Inhaled Corticosteroids and the Risk of Fractures in Older Adults: A Systematic Review and Meta-Analysis","volume":"31","author":"Etminan","year":"2008","journal-title":"Drug Saf"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.4968","article-title":"Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures","volume":"157","author":"Egeberg","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"106374","DOI":"10.1016\/j.rmed.2021.106374","article-title":"Corticosteroids and Bone Health in People With Asthma: A Systematic Review and Meta-Analysis","volume":"181","author":"Chalitsios","year":"2021","journal-title":"Respir Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e008554","DOI":"10.1136\/bmjopen-2015-008554","article-title":"Bone Mineral Density and Fracture Risk With Long-Term Use of Inhaled Corticosteroids in Patients With Asthma: Systematic Review and Meta-Analysis","volume":"5","author":"Loke","year":"2015","journal-title":"BMJ Open"},{"key":"B67","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/thx.2011.160028","article-title":"Risk of Fractures With Inhaled Corticosteroids in COPD: Systematic Review and Meta-Analysis of Randomised Controlled Trials and Observational Studies","volume":"66","author":"Loke","year":"2011","journal-title":"Thorax"},{"key":"B68","doi-asserted-by":"publisher","first-page":"CD002991","DOI":"10.1002\/14651858.CD002991.pub3","article-title":"Inhaled Corticosteroids for Stable Chronic Obstructive Pulmonary Disease","volume":"7","author":"Yang","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnx324","article-title":"The Effect of Epidural Steroid Injections on Bone Mineral Density and Vertebral Fracture Risk: A Systematic Review and Critical Appraisal of Current Literature","volume":"19","author":"Kerezoudis","year":"2018","journal-title":"Pain Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203171","article-title":"Periarticular and Generalised Bone Loss in Patients With Early Rheumatoid Arthritis: Influence of Alendronate and Intra-Articular Glucocorticoid Treatment. Post Hoc Analyses From the CIMESTRA Trial","volume":"73","author":"Jensen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00662-7","article-title":"Bone Mineral Density in Relation to Efficacy and Side Effects of Budesonide and Prednisolone in Crohn's Disease","volume":"3","author":"Schoon","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwy018","article-title":"Budesonide for the Induction and Maintenance of Remission in Crohn's Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration","volume":"1","author":"Kuenzig","year":"2018","journal-title":"J Can Assoc Gastroenterol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03155.x","article-title":"Pharmacokinetics and Bone Effects of Budesonide in Primary Biliary Cirrhosis","volume":"24","author":"Rautiainen","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"B74","doi-asserted-by":"publisher","first-page":"CD011996","DOI":"10.1002\/14651858.CD011996.pub2","article-title":"Intranasal Steroids Versus Placebo or No Intervention for Chronic Rhinosinusitis","volume":"4","author":"Chong","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.07.006","article-title":"Bone Disease Following Solid Organ Transplantation: A Narrative Review and Recommendations for Management From The European Calcified Tissue Society","volume":"127","author":"Anastasilakis","year":"2019","journal-title":"Bone"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203249","article-title":"EULAR Evidence-Based and Consensus-Based Recommendations on the Management of Medium to High-Dose Glucocorticoid Therapy in Rheumatic Diseases","volume":"72","author":"Duru","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05664-x","article-title":"Methotrexate Osteopathy: Five Cases and Systematic Literature Review","volume":"32","author":"Robin","year":"2021","journal-title":"Osteoporos Int"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-3014-2","article-title":"Longitudinal Practice Patterns of Prophylaxis of Glucocorticoid-Induced Osteoporosis in Patients With Polymyalgia Rheumatica","volume":"34","author":"Naranjo","year":"2014","journal-title":"Rheumatol Int"},{"key":"B79","article-title":"Osteoporosis Management Among Chronic Glucocorticoid Users: A Systematic Review","volume":"21","author":"Albaum","year":"2014","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41533-020-0162-6","article-title":"A Retrospective Database Study of Oral Corticosteroid and Bisphosphonate Prescribing Patterns in England","volume":"30","author":"Chalitsios","year":"2020","journal-title":"NPJ Prim Care Respir Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2562-8","article-title":"Increase in Prophylaxis of Glucocorticoid-Induced Osteoporosis by Pharmacist Feedback: A Randomised Controlled Trial","volume":"25","author":"Klop","year":"2014","journal-title":"Osteoporos Int"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-0977-z","article-title":"Community Pharmacist-Initiated Screening Program for Osteoporosis: Randomized Controlled Trial","volume":"21","author":"Yuksel","year":"2010","journal-title":"Osteoporos Int"},{"key":"B83","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1524-4733.2005.04007.x","article-title":"An Evaluation of Managing and Educating Patients on the Risk of Glucocorticoid-Induced Osteoporosis","volume":"8","author":"McDonough","year":"2005","journal-title":"Value Health"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/art.22462","article-title":"Barriers in the Management of Glucocorticoid-Induced Osteoporosis","volume":"57","author":"Guzman-Clark","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.09.011","article-title":"Analysis of Quality Improvement Efforts in Preventing Glucocorticoid-Induced Osteoporosis","volume":"44","author":"Tory","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B86","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jocd.2018.03.009","article-title":"Prevention of Glucocorticoid-Induced Osteoporosis: Clinical Audit to Evaluate the Implementation of National Osteoporosis Guideline Group 2017 Guidelines in a Primary Care Setting","volume":"22","author":"Carter","year":"2019","journal-title":"J Clin Densitom"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13310","article-title":"Effects of Quality Indicator Monitoring for Glucocorticoid-Induced Osteoporosis and Trends of Drug Treatment in a Japanese Hospital","volume":"21","author":"Suda","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.6.591","article-title":"Challenges in Improving the Quality of Osteoporosis Care for Long-Term Glucocorticoid Users: A Prospective Randomized Trial","volume":"167","author":"Curtis","year":"2007","journal-title":"Arch Intern Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-1114-8","article-title":"Cost-Effectiveness of Multifaceted Evidence Implementation Programs for the Prevention of Glucocorticoid-Induced Osteoporosis","volume":"21","author":"Beukelman","year":"2010","journal-title":"Osteoporos Int"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1675-5","article-title":"Practice Patterns in the Diagnosis and Treatment of Osteoporosis After a Fragility Fracture: A Systematic Review","volume":"15","author":"Elliot-Gibson","year":"2004","journal-title":"Osteoporos Int"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23279","article-title":"American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.21962","article-title":"Interventions to Prevent Falls in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"319","author":"Guirguis-Blake","year":"2018","journal-title":"JAMA"},{"key":"B93","doi-asserted-by":"publisher","first-page":"CD006349","DOI":"10.1002\/14651858.CD006349.pub4","article-title":"Percutaneous Vertebroplasty for Osteoporotic Vertebral Compression Fracture","volume":"11","author":"Buchbinder","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B94","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.3653","article-title":"The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report","volume":"34","author":"Ebeling","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/ans.13428","article-title":"Risk Factors for New Vertebral Compression Fractures After Vertebroplasty: A Meta-Analysis","volume":"86","author":"Cao","year":"2016","journal-title":"ANZ J Surg"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-1958-1","article-title":"A Framework for the Development of Guidelines for the Management of Glucocorticoid-Induced Osteoporosis","volume":"23","author":"Lekamwasam","year":"2012","journal-title":"Osteoporos Int"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4178","article-title":"Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained","volume":"36","author":"Eastell","year":"2021","journal-title":"J Bone Miner Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cca.2016.06.036","article-title":"Clinical Usefulness of Bone Turnover Marker Concentrations in Osteoporosis","volume":"467","author":"Morris","year":"2017","journal-title":"Clin Chim Acta"},{"key":"B99","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cca.2020.12.023","article-title":"Metabolism, Analytical Considerations and Plans to Standardize or Harmonize Assays for the Reference Bone Turnover Markers PINP and Beta-CTX in Blood","volume":"515","author":"Bhattoa","year":"2021","journal-title":"Clin Chim Acta"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-021-00816-5","article-title":"A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (Ss-CTX): A Report From the IFCC-IOF Committee for Bone Metabolism (C-Bm)","volume":"108","author":"Cavalier","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"B101","doi-asserted-by":"crossref","first-page":"pp","DOI":"10.1007\/978-94-007-7693-7_23","article-title":"Bone Turnover Markers and Glucocorticoid Treatments","volume-title":"Biomarkers in Bone Disease","author":"Devogelaer","year":"2017"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.04.025","article-title":"The Osteoblast: Linking Glucocorticoid-Induced Osteoporosis and Hyperglycaemia? A post-hoc Analysis of a Randomised Clinical Trial","volume":"112","author":"van Bommel","year":"2018","journal-title":"Bone"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0751","article-title":"Prednisone Affects Inflammation, Glucose Tolerance, and Bone Turnover Within Hours of Treatment in Healthy Individuals","volume":"166","author":"Kauh","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12891-016-1135-3","article-title":"Safety and Pharmacodynamic Dose Response of Short-Term Prednisone in Healthy Adult Subjects: A Dose Ranging, Randomized, Placebo-Controlled, Crossover Study","volume":"17","author":"Fleishaker","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.041125","article-title":"Effects of Low-Dose Prednisone on Bone Metabolism","volume":"20","author":"Ton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel249","article-title":"Individual Fracture Risk and the Cost-Effectiveness of Bisphosphonates in Patients Using Oral Glucocorticoids","volume":"46","author":"van Staa","year":"2007","journal-title":"Rheumatol (Oxford)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1643-0","article-title":"Cost-Effectiveness of Risedronate for the Treatment of Osteoporosis and Prevention of Fractures in Postmenopausal Women","volume":"15","author":"Kanis","year":"2004","journal-title":"Osteoporos Int"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1524-7","article-title":"Guidance for the Adjustment of FRAX According to the Dose of Glucocorticoids","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-1923-3","article-title":"High-Dose Glucocorticoid Treatment Induces Rapid Loss of Trabecular Bone Mineral Density and Lean Body Mass","volume":"17","author":"Natsui","year":"2006","journal-title":"Osteoporos Int"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-021-00875-8","article-title":"MOF\/Hip Fracture Ratio in a Belgian Cohort of Post-Menopausal Women (FRISBEE): Potential Impact on the FRAX(R) Score","volume":"109","author":"Mugisha","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10532","article-title":"Independent External Validation of FRAX and Garvan Fracture Risk Calculators: A Sub-Study of the FRISBEE Cohort","volume":"5","author":"Baleanu","year":"2021","journal-title":"JBMR Plus"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2734","article-title":"A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX","volume":"31","author":"McCloskey","year":"2016","journal-title":"J Bone Miner Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jbmr.3877","article-title":"Secondary Fracture Prevention: Consensus Clinical Recommendations From a Multistakeholder Coalition","volume":"35","author":"Conley","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00490","article-title":"Microstructure, and Strength Can Discriminate Vertebral Fracture in Patients on Long-Term Steroid Treatment","volume":"103","author":"Shen","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4591-9","article-title":"Abnormal Microarchitecture and Stiffness in Postmenopausal Women Using Chronic Inhaled Glucocorticoids","volume":"29","author":"Liu","year":"2018","journal-title":"Osteoporos Int"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3077-2","article-title":"Cortical Thinning and Progressive Cortical Porosity in Female Patients With Systemic Lupus Erythematosus on Long-Term Glucocorticoids: A 2-Year Case-Control Study","volume":"26","author":"Zhu","year":"2015","journal-title":"Osteoporos Int"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2177","article-title":"Abnormalities in Cortical Bone, Trabecular Plates, and Stiffness in Postmenopausal Women Treated With Glucocorticoids","volume":"99","author":"Sutter","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.10.036","article-title":"High Resolution Quantitative Computed Tomography-Based Assessment of Trabecular Microstructure and Strength Estimates by Finite-Element Analysis of the Spine, But Not DXA, Reflects Vertebral Fracture Status in Men With Glucocorticoid-Induced Osteoporosis","volume":"52","author":"Graeff","year":"2013","journal-title":"Bone"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2497","article-title":"Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis","volume":"30","author":"Mellibovsky","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.02.005","article-title":"Advanced Imaging Assessment of Bone Fragility in Glucocorticoid-Induced Osteoporosis","volume":"48","author":"Kalpakcioglu","year":"2011","journal-title":"Bone"},{"key":"B121","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00198-018-4798-9","article-title":"Cost-Effectiveness of Implementing Guidelines for the Treatment of Glucocorticoid-Induced Osteoporosis in Japan","volume":"30","author":"Moriwaki","year":"2019","journal-title":"Osteoporos Int"},{"key":"B122","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/1471-2474-13-213","article-title":"The Cost Effectiveness of Teriparatide as a First-Line Treatment for Glucocorticoid-Induced and Postmenopausal Osteoporosis Patients in Sweden","volume":"13","author":"Murphy","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"B123","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta11070","article-title":"Glucocorticoid-Induced Osteoporosis: A Systematic Review and Cost-Utility Analysis","volume":"11","author":"Kanis","year":"2007","journal-title":"Health Technol Assess"},{"key":"B124","first-page":"93","article-title":"Pharmacoeconomic Analysis of Osteoporosis Treatment With Risedronate","volume":"23","author":"Brecht","year":"2003","journal-title":"Int J Clin Pharmacol Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.2020.27.4.247","article-title":"Intervention Thresholds for Treatment in Patients With Glucocorticoid-Induced Osteoporosis: Systematic Review of Guidelines","volume":"27","author":"Lee","year":"2020","journal-title":"J Bone Metab"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1258\/rsmsmj.54.1.21","article-title":"Research Committee of the British Thoracic, Hormone Replacement Therapy (HRT) or Etidronate for Osteoporosis in Postmenopausal Asthmatics on Glucocorticoids: A Randomised Factorial Trial","volume":"54","author":"Campbell","year":"2009","journal-title":"Scott Med J"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000313","article-title":"One-Year Effects of Glucocorticoids on Bone Density: A Meta-Analysis in Cohorts on High and Low-Dose Therapy","volume":"2","author":"Lems","year":"2016","journal-title":"RMD Open"},{"key":"B128","doi-asserted-by":"publisher","first-page":"CD005015","DOI":"10.1002\/14651858.CD005015.pub4","article-title":"Interventions for Preventing Bone Disease in Kidney Transplant Recipients","volume":"10","author":"Palmer","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.10.049","article-title":"Efficacy and Safety of Bisphosphonates for Osteoporosis or Osteopenia in Cardiac Transplant Patients: A Meta-Analysis","volume":"47","author":"Zhao","year":"2015","journal-title":"Transplant Proc"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.00976.x","article-title":"Effect of Bisphosphonates on Bone Mineral Density in Liver Transplant Patients: A Meta-Analysis and Systematic Review of Randomized Controlled Trials","volume":"23","author":"Kasturi","year":"2010","journal-title":"Transpl Int"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1448","article-title":"Prevention of Fractures After Solid Organ Transplantation: A Meta-Analysis","volume":"96","author":"Stein","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05294-y","article-title":"The Effect of Calcium and Vitamin D Compounds on Bone Mineral Density in Patients Undergoing Glucocorticoid Therapies: A Network Meta-Analysis","volume":"40","author":"Deng","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"CD000952","DOI":"10.1002\/14651858.CD000952","article-title":"Calcium and Vitamin D for Corticosteroid-Induced Osteoporosis","volume":"2","author":"Homik","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.7148","article-title":"Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: A Randomized Clinical Trial","volume":"176","author":"Bischoff-Ferrari","year":"2016","journal-title":"JAMA Intern Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.11889","article-title":"Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial","volume":"322","author":"Burt","year":"2019","journal-title":"JAMA"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12759","article-title":"Vitamin D Supplementation and Risk of Falling: Outcomes From the Randomized, Placebo-Controlled D-Health Trial","volume":"12","author":"Waterhouse","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa228","article-title":"Pharmacological Prevention of Fractures in Patients Undergoing Glucocorticoid Therapies: A Systematic Review and Network Meta-Analysis","volume":"60","author":"Deng","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B138","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00198-004-1614-5","article-title":"Prevention and Treatment of Glucocorticoid-Induced Osteoporosis With Active Vitamin D3 Analogues: A Review With Meta-Analysis of Randomized Controlled Trials Including Organ Transplantation Studies","volume":"15","author":"de Nijs","year":"2004","journal-title":"Osteoporos Int"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/BF02030075","article-title":"Prevention of Glucocorticoid-Induced Osteopenia: Effect of Oral 25-Hydroxyvitamin D and Calcium","volume":"8","author":"Di Munno","year":"1989","journal-title":"Clin Rheumatol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s002239900206","article-title":"Calcitonin, Etidronate, and Calcidiol Treatment in Bone Loss After Cardiac Transplantation","volume":"60","author":"Garcia-Delgado","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"B141","article-title":"Efficiency of Preventive Treatment of Glucocorticoid-Induced Osteoporosis With 25-Hydroxyvitamin D3 and Calcium in Kidney Transplant Patients","volume":"28","author":"Talalaj","year":"1996","journal-title":"Transplant Proc"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055218","article-title":"Calcium Plus Vitamin D Supplementation and the Risk of Fractures","volume":"354","author":"Jackson","year":"2006","journal-title":"N Engl J Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz212","article-title":"Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial","volume":"105","author":"Billington","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B144","article-title":"A Cost Effectiveness Analysis of Calcium and Vitamin D Supplementation, Etidronate, and Alendronate in the Prevention of Vertebral Fractures in Women Treated With Glucocorticoids","volume":"30","author":"Buckley","year":"2003","journal-title":"J Rheumatol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-Year Effects of Alendronate on Bone Mineral Density and Vertebral Fracture in Patients Receiving Glucocorticoids: A Randomized, Double-Blind, Placebo-Controlled Extension Trial","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate Therapy Prevents Corticosteroid-Induced Bone Loss: A Twelve-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes079","article-title":"Quality Assurance Study of the Use of Preventative Therapies in Glucocorticoid-Induced Osteoporosis in Early Inflammatory Arthritis: Results From the CATCH Cohort","volume":"51","author":"McKeown","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.5.919","article-title":"Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: A Comparison of Calcitriol, Vitamin D Plus Calcium, and Alendronate Plus Calcium","volume":"18","author":"Sambrook","year":"2003","journal-title":"J Bone Miner Res"},{"key":"B149","doi-asserted-by":"publisher","first-page":"CD001347","DOI":"10.1002\/14651858.CD001347.pub2","article-title":"Bisphosphonates for Steroid-Induced Osteoporosis","volume":"10","author":"Allen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243851","article-title":"Efficacy and Safety of 18 Anti-Osteoporotic Drugs in the Treatment of Patients With Osteoporosis Caused by Glucocorticoid: A Network Meta-Analysis of Randomized Controlled Trials","volume":"15","author":"Liu","year":"2020","journal-title":"PloS One"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143453","article-title":"Raloxifene for Prevention of Glucocorticoid-Induced Bone Loss: A 12-Month Randomised Double-Blinded Placebo-Controlled Trial","volume":"70","author":"Mok","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3476-4","article-title":"Efficacy of Osteoporosis Pharmacotherapies in Preventing Fracture Among Oral Glucocorticoid Users: A Network Meta-Analysis","volume":"27","author":"Amiche","year":"2016","journal-title":"Osteoporos Int"},{"key":"B153","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13075-021-02564-1","article-title":"Effectiveness of Bazedoxifene in Preventing Glucocorticoid-Induced Bone Loss in Rheumatoid Arthritis Patients","volume":"23","author":"Cho","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012691","article-title":"Effects of Alendronate for Treatment of Glucocorticoid-Induced Osteoporosis: A Meta-Analysis of Randomized Controlled Trials","volume":"97","author":"Wang","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B155","doi-asserted-by":"publisher","first-page":"rkaa008","DOI":"10.1093\/rap\/rkaa008","article-title":"The Therapeutic Efficacy of Denosumab for the Loss of Bone Mineral Density in Glucocorticoid-Induced Osteoporosis: A Meta-Analysis","volume":"4","author":"Yamaguchi","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"B156","doi-asserted-by":"publisher","first-page":"116396","DOI":"10.1016\/j.bone.2022.116396","article-title":"Delayed Initiation of Anti-Osteoporosis Medications Increases Subsequent Hip and Vertebral Fractures in Patients on Long-Term Glucocorticoid Therapy: A Nationwide Health Insurance Claims Database Study in Japan","volume":"160","author":"Iki","year":"2022","journal-title":"Bone"},{"key":"B157","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"International Task Force on Osteonecrosis of the, Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218758","article-title":"Concomitant Use of Oral Glucocorticoids and Proton Pump Inhibitors and Risk of Osteoporotic Fractures Among Patients With Rheumatoid Arthritis: A Population-Based Cohort Study","volume":"80","author":"Abtahi","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.25011\/cim.v40i3.28394","article-title":"Head-To-Head Comparisons of Bisphosphonates and Teriparatide in Osteoporosis: A Meta-Analysis","volume":"40","author":"Liu","year":"2017","journal-title":"Clin Invest Med"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz023","article-title":"Efficacy and Safety of First- and Second-Line Drugs to Prevent Glucocorticoid-Induced Fractures","volume":"105","author":"Ding","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (HORIZON): A Multicentre, Double-Blind, Double-Dummy, Randomised Controlled Trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: A Multicentre, Randomised, Double-Blind, Active-Controlled, Double-Dummy, non-Inferiority Study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1002\/art.24879","article-title":"Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis: Thirty-Six-Month Results of a Randomized, Double-Blind, Controlled Trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B166","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/ejhpharm-2017-001258","article-title":"Adherence and Preference of Intravenous Zoledronic Acid for Osteoporosis Versus Other Bisphosphonates","volume":"26","author":"Fobelo Lozano","year":"2019","journal-title":"Eur J Hosp Pharm"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and Denosumab, Alone or Combined, in Women With Postmenopausal Osteoporosis: The DATA Study Randomised Trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110947","article-title":"Effectiveness of Teriparatide in Postmenopausal Women With Osteoporosis and Glucocorticoid Use: 3-Year Results From the EFOS Study","volume":"39","author":"Karras","year":"2012","journal-title":"J Rheumatol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac014","article-title":"Comparable Efficacy of Denosumab and Romosozumab in Patients With Rheumatoid Arthritis Receiving Glucocorticoid Administration","author":"Kobayakawa","year":"2022","journal-title":"Mod Rheumatol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1007\/s002230001146","article-title":"Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.8040","article-title":"Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone","volume":"318","author":"Axelsson","year":"2017","journal-title":"JAMA"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01912","article-title":"Alendronate Use and the Risk of Nonvertebral Fracture During Glucocorticoid Therapy: A Retrospective Cohort Study","volume":"103","author":"Bergman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3318","article-title":"Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses","volume":"33","author":"Amiche","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-3022-9","article-title":"Fracture Rate Associated With Quality Metric-Based Anti-Osteoporosis Treatment in Glucocorticoid-Induced Osteoporosis","volume":"26","author":"Overman","year":"2015","journal-title":"Osteoporos Int"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-2060-4","article-title":"Oral Bisphosphonates Reduce the Risk of Clinical Fractures in Glucocorticoid-Induced Osteoporosis in Clinical Practice","volume":"24","author":"Thomas","year":"2013","journal-title":"Osteoporos Int"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical Femur Fracture Risk Versus Fragility Fracture Prevention With Bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.7326\/M21-2512","article-title":"Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study","volume":"175","author":"Hayes","year":"2022","journal-title":"Ann Intern Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4188","article-title":"Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study","volume":"36","author":"Gilsenan","year":"2021","journal-title":"J Bone Miner Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone Health in Cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01696","article-title":"Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1002\/art.40874","article-title":"Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4551","article-title":"Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment","author":"Geusens","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B184","doi-asserted-by":"publisher","first-page":"115902","DOI":"10.1016\/j.bone.2021.115902","article-title":"Denosumab Versus Alendronate in Long-Term Glucocorticoid Users: A 12-Month Randomized Controlled Trial","volume":"146","author":"Mok","year":"2021","journal-title":"Bone"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-021-01128-7","article-title":"[Glucocorticoid-Induced Osteoporosis-Focus Treatment (Part 2)]","volume":"81","author":"Oelzner","year":"2022","journal-title":"Z Rheumatol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jbspin.2014.10.001","article-title":"2014 Update of Recommendations on the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis","volume":"81","author":"Briot","year":"2014","journal-title":"Joint Bone Spine"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107142","article-title":"Bone-Density Testing Interval and Transition to Osteoporosis in Older Women","volume":"366","author":"Gourlay","year":"2012","journal-title":"N Engl J Med"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3164","article-title":"Screening for Atypical Femur Fractures Using Extended Femur Scans by DXA","volume":"32","author":"van de Laarschot","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05601-y","article-title":"Cumulative Incidence of Femoral Localized Periosteal Thickening (Beaking) Preceding Atypical Femoral Fractures in Patients With Rheumatoid Arthritis","volume":"32","author":"Sato","year":"2021","journal-title":"Osteoporos Int"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2019.07.003","article-title":"Detection of Atypical Femur Fractures","volume":"22","author":"Cheung","year":"2019","journal-title":"J Clin Densitom"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.05.016","article-title":"Trabecular Bone Score (TBS) as a New Complementary Approach for Osteoporosis Evaluation in Clinical Practice","volume":"78","author":"Harvey","year":"2015","journal-title":"Bone"},{"key":"B193","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00198-015-3211-1","article-title":"Bone Status in Glucocorticoid-Treated Men and Women","volume":"27","author":"Leib","year":"2016","journal-title":"Osteoporos Int"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez464","article-title":"Trabecular Bone Score Improves Fracture Risk Assessment in Glucocorticoid-Induced Osteoporosis","volume":"59","author":"Florez","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B195","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1055\/a-1528-7261","article-title":"Clinical Utility of Trabecular Bone Score (TBS) in Fracture Risk Assessment of Patients With Rheumatic Diseases Treated With Glucocorticoids","volume":"53","author":"Nowakowska-Plaza","year":"2021","journal-title":"Horm Metab Res"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14164","article-title":"Discriminative Ability of Trabecular Bone Score Over Bone Mineral Density for Vertebral and Fragility Fracture in Patients Treated With Long-Term and Low-Dose Glucocorticoid","volume":"24","author":"Lee","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1002\/art.39726","article-title":"Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.12.021","article-title":"Bone Formation Markers in Patients With Glucocorticoid-Induced Osteoporosis Treated With Teriparatide or Alendronate","volume":"46","author":"Eastell","year":"2010","journal-title":"Bone"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.908727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T13:17:14Z","timestamp":1654780634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.908727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":198,"alternative-id":["10.3389\/fendo.2022.908727"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.908727","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"article-number":"908727"}}